CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,850 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03324633
NCT03324633N/ACompleted

Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With Hepatitis C and Human Immunodeficiency Virus (Collaboration Inter Cohortes et Centres Cliniques de Sujets Co-infectés Par Les Virus de l'immunodéficence Humaine et de l'hépatite C)

ANRS, Emerging Infectious Diseases·observational·Posted Oct 30, 2017·Updated Aug 2, 2023

In Brief

An observational study for HIV and Hepatitis C. Completed, enrolled 1,850 participants.

Detailed Summary

The ANRS CO13 HEPAVIH cohort is a prospective and multicentric cohort created in 2005 with the originality to cover two therapeutic domains of key importance, AIDS and hepatitis C. The cohort, is unique in Europe with more than 1800 participants followed over 10 years including quality of life and compliance to treatment data.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, Hepatitis C
Countries--

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 30, 2017
Enrollment StartJun 1, 2005
Primary CompletionSep 1, 2017
Study CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 12.3 yearsPosted 8.7 years ago